Pidotimod (CAS: 121808-62-6) Product Introduction
1. Product Overview
Pidotimod (CAS 121808-62-6) is a high-purity synthetic immunomodulatory intermediate and biochemical reagent for pharmaceutical R&D institutions and immunology laboratories, solving low bioavailability, poor acid stability and impure batch quality of common immunomodulator raw materials.
2. Core Product Categories
Pharmaceutical Intermediate, Immunology Research Reagent, Biochemical Raw Material, Immune Regulation Active Substance
3. Target Crowd
Pharmaceutical formulation R&D teams, immunological research laboratories, biomedical experimental institutions and drug intermediate processing manufacturers
4. Core Solved Pain Points
· Common immune regulatory raw materials suffer from low gastric acid stability and are prone to structural degradation in acidic environments
· Ordinary immunomodulator intermediates have low bioavailability, limiting experimental and pharmaceutical application effects
· Low-purity products contain residual impurities, causing unstable experimental data and interfering immune activity detection
· Conventional raw materials have short storage life, increasing batch replacement cost and experimental repeatability risks
5. Core Selling Points
· Delivers 98.5% minimum HPLC purity calculated on dry basis, effectively eliminating impurity interference for immune mechanism experiments and drug formulation research.
· Maintains 45% standard oral bioavailability, 20% higher than common linear peptide immunomodulators, ensuring stable biological activity.
· Possesses excellent acid resistance structural stability, avoiding molecular degradation in simulated gastric acid environments and retaining complete immune regulation activity.
· Controls total residual impurities below 1.0% and burning residue below 0.5%, meeting pharmaceutical intermediate grade application standards.
6. Core Product Parameters
This product has a fixed CAS number of 121808-62-6 with a molecular formula of C9H12N2O4S and molecular weight of 244.27 g/mol. It appears as white to off-white solid powder at 25°C, with a melting point ranging from 194°C to 198°C. The minimum HPLC purity reaches 98.5% on dry basis. The powder form stored at 2°C to 8°C maintains stable quality for 24 months, while -20°C sealed storage supports 36-month shelf life. It has a boiling point of 663.0°C at 760 mmHg and a density of 1.5 g/cm³.
7. Application Scenarios
Immunology laboratories adopt this high-purity reagent to carry out macrophage phagocytosis and cellular immune response mechanism research.
Pharmaceutical R&D teams apply the product as a core intermediate for the development of immune regulation pharmaceutical formulations.
Biomedical research institutions use the acid-stable pidotimod to complete simulated gastrointestinal drug activity experiments.
Drug intermediate manufacturers take this standardized raw material for batch preparation of immunomodulatory drug precursors.
8. Frequently Asked Questions
Q1: What is the core advantage of pidotimod over ordinary peptide immune regulators?
It features stable acid-resistant structure and 45% bioavailability, resisting gastric acid degradation and delivering more stable immune regulation activity than linear peptides.
Q2: What purity standard does this pidotimod product meet?
It reaches 98.5% minimum HPLC purity on dry basis, with strictly controlled residual impurities, compliant with pharmaceutical intermediate and precision experimental standards.
Q3: How to store pidotimod to maximize its service life?
Seal and store powder samples at 2°C to 8°C for 24-month validity, or store at -20°C for 36 months to retain complete biological activity.
Q4: What experimental research fields is pidotimod suitable for?
It adapts to macrophage activity detection, cellular immune mechanism exploration and immune drug formulation screening in immunology and biomedical research.
Q5: Can pidotimod maintain stability in acidic experimental environments?
Yes, its special cyclic structure resists acidic degradation, maintaining complete molecular structure and biological activity in simulated gastric acid conditions.
Q6: What causes the stable batch consistency of this pidotimod product?
Strict impurity control and standardized purification process reduce batch difference, ensuring repeatable experimental data and stable pharmaceutical application effects.
